Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Operating Leases (2018 - 2025)

Cytosorbents (CTSO) has disclosed Operating Leases for 8 consecutive years, with $12.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 4.12% year-over-year to $12.1 million, compared with a TTM value of $12.1 million through Sep 2025, down 4.12%, and an annual FY2024 reading of $12.4 million, down 3.51% over the prior year.
  • Operating Leases was $12.1 million for Q3 2025 at Cytosorbents, down from $12.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $13.8 million in Q4 2021 and bottomed at $461064.0 in Q1 2021.
  • Average Operating Leases over 5 years is $12.3 million, with a median of $13.0 million recorded in 2023.
  • The sharpest move saw Operating Leases tumbled 52.48% in 2021, then skyrocketed 2756.95% in 2022.
  • Year by year, Operating Leases stood at $13.8 million in 2021, then decreased by 4.92% to $13.1 million in 2022, then decreased by 1.87% to $12.9 million in 2023, then dropped by 3.51% to $12.4 million in 2024, then dropped by 3.16% to $12.1 million in 2025.
  • Business Quant data shows Operating Leases for CTSO at $12.1 million in Q3 2025, $12.2 million in Q2 2025, and $12.3 million in Q1 2025.